EcoDrugPlus

Prostaglandin E Receptor 4 (Subtype Ep4) A

Ensembl ID : ENSPMAG00000008377
Gene Symbol: PTGER4A
1 Cross references
334 Possible Orthologues:

Proteasome 20s Subunit Alpha 2a

Ensembl ID : ENSPMAG00000001926
Gene Symbol: PSMA2A
1 Cross references
287 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSPMAG00000005903
Gene Symbol: PSMA3
1 Cross references
249 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSPMAG00000000273
Gene Symbol: PSMA4
1 Cross references
253 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSPMAG00000003219
Gene Symbol: PSMA5
1 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 6a

Ensembl ID : ENSPMAG00000003249
Gene Symbol: PSMA6A
1 Cross references
334 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSPMAG00000007980
Gene Symbol: PSMB2
1 Cross references
222 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSPMAG00000002061
Gene Symbol: PSMB3
1 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSPMAG00000008432
Gene Symbol: PSMB4
1 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSPMAG00000002537
Gene Symbol: PSMB7
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSPMAG00000004367
Gene Symbol: PSMD2
1 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4a

Ensembl ID : ENSPMAG00000003046
Gene Symbol: PSMD4A
1 Cross references
291 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).